Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 168

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma

Open access
Waguespack, Steven G, Drilon, Alexander, Lin, Jessica J, Brose, Marcia S, McDermott, Ray, Almubarak, Mohammed, Bauman, Jessica, Casanova, Michela, Krishnamurthy, Anuradha, Kummar, Shivaani, Leyvraz, Serge, Oh, Do-Youn, Park, Keunchil, Sohal, Davendra, Sherman, Eric, Norenberg, Ricarda, Silvertown, Josh D, Brega, Nicoletta, Hong, David S, Cabanillas, Maria E · 2022 · European Journal of Endocrinology

Abstract

Objective: Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor with demonstrated efficacy across various TRK fusion-positive solid tumours. We assessed the efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma (TC). Methods: We pooled data from three phase I/II larotrectinib clinical trials (NCT02576431, NCT02122913, and NCT02637687). The primary endpoint was the investigator-assessed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors v1.1. Secondary endpoints included duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. Data cut-off: July 2020. Results: Twenty-nine patients (median age: 60; range: 6–80) with TRK fusion-positive TC were treated. Tumour histology was papillary (PTC) in 20 (69%) patients, follicular (FTC) in 2 (7%), and anaplastic (ATC) in 7 (24%) patients. Among 28 evaluable patients, ORR was 71% (95% CI: 51–87); best responses were complete response in 2 (7%) patients, partial response in 18 (64%), stable disease in 4 (14%), progressive disease in 3 (11%), and undetermined in 1 (4%) due to clinical progression prior to the first post-baseline assessment. ORR was 86% (95% CI: 64–97) for PTC/FTC and 29% (95% CI 4–71) for ATC. Median time to response was 1.87 months (range 1.64–3.68). The 24-month DoR, PFS, and OS rates were 81, 69, and 76%, respectively. Treatment-related adverse events were mainly grades 1–2. Conclusion: In TRK fusion-positive TC, larotrectinib demonstrates rapid and durable disease control and a favourable safety profile in patients with advanced disease requiring systemic therapy. Significance statement: NTRK gene fusions are known oncogenic drivers and have been identified in various histologies of thyroid carcinoma, most commonly in papillary thyroid carcinoma. This is the first publication specifically studying a TRK inhibitor in a cohort of TRK fusion-positive thyroid carcinoma patients. In the current study, the highly selective TRK inhibitor larotrectinib showed durable antitumour efficacy and a favourable safety profile in patients with TRK fusion-positive thyroid carcinoma. Our findings show that patients with advanced non-medullary thyroid carcinoma who may require systemic therapy could be considered for testing for gene fusions by next-generation sequencing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1530/eje-21-1259

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 168

Metadata

Authors
Waguespack, S. G., Drilon, A., Lin, J. J., Brose, M. S., McDermott, R., Almubarak, M., Bauman, J., Casanova, M., Krishnamurthy, A., Kummar, S., Leyvraz, S., Oh, D.-Y., Park, K., Sohal, D., Sherman, E., Norenberg, R., Silvertown, J. D., Brega, N., Hong, D. S., & Cabanillas, M. E.
Venue
European Journal of Endocrinology
Published
2022-06-01
Volume
186
Issue
6
Pages
631-643
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
OpenAlex
W4220804542
Cited by
168
References
4
FWCI
20.48
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. https://app.cochat.ai/papers/10.1530/eje-21-1259
The paper
Waguespack, S. G., Drilon, A., Lin, J. J., Brose, M. S., McDermott, R., Almubarak, M., Bauman, J., Casanova, M., Krishnamurthy, A., Kummar, S., Leyvraz, S., Oh, D.-Y., Park, K., Sohal, D., Sherman, E., Norenberg, R., Silvertown, J. D., Brega, N., Hong, D. S., & Cabanillas, M. E. (2022). Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. European Journal of Endocrinology. https://doi.org/10.1530/eje-21-1259

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.